

Treatment of Age-Related Macular Degeneration

Yaser Elhams*

ABSTRACT

Aging macular degeneration (AMD) is a leading reason for irreversible loss of vision, particularly in the elderly. This review takes into account current management options for AMD, both traditional and emerging approaches, to offer an overview of effective management. A qualitative literature review from 2019 to 2024 was conducted with Google Scholar and PubMed using the keywords "AMD treatment." Peer-reviewed publications regarding intravitreal injections and experimental treatments were accessed. The review highlights the effectiveness of intravitreal injections of VEGF inhibitors as the standard treatment for the exudative form of AMD. There are no effective treatments, though, for late-stage dry AMD. In particular, technological strides in cloud computing and artificial intelligence (AI) have promised early diagnosis and treatment planning. The review explains the significance of continued research into treatment of dry AMD. In conclusion, while great leaps have been made in the therapy of exudative AMD using VEGF inhibitors and early detection using AI, more studies and collaboration between healthcare providers must be undertaken to develop effective therapies for dry AMD and optimize patient outcomes.

Keywords: *age-related macular degeneration; AMD treatment; VEGF inhibitors; artificial intelligence, macula dystrophy*

Bahrain Med Bull 2025; 45 (4): 2676 - 2679

* Department of Ophthalmology and ENT,
Medical college, Umm Al-Qura University,
Makkah, Saudi Arabia.
E-mail: ymhams@uqu.edu.sa